VistaGen Therapeutics Inc. (VTGN)

The total asset value of VistaGen Therapeutics Inc. (VTGN) stood at $ 34 Mln as on 31-Dec-22

The share price of VistaGen Therapeutics Inc. (VTGN) is $3.72 (NASDAQ) as of 28-Nov-2023 16:00 EST. VistaGen Therapeutics Inc. (VTGN) has given a return of -45.59% in the last 3 years.

VistaGen Therapeutics Inc. (VTGN) has a market capitalisation of $ 16 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of VistaGen Therapeutics Inc. (VTGN) is 0.84 times as on 09-Jun-2023, a -0.67% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of VistaGen Therapeutics Inc. (VTGN) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the VistaGen Therapeutics Inc. (VTGN) and enter the required number of quantities and click on buy to purchase the shares of VistaGen Therapeutics Inc. (VTGN).

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

The CEO & director of Mr. Shawn K. Singh J.D.. is VistaGen Therapeutics Inc. (VTGN), and CFO & Sr. VP is Mr. Jerrold D. Dotson CPA, CPA.

The promoters of VistaGen Therapeutics Inc. (VTGN) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

No, TTM profit after tax of VistaGen Therapeutics Inc. (VTGN) was $-54 Mln.